These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29890284)

  • 1. MS methods to study macromolecule-ligand interaction: Applications in drug discovery.
    Riccardi Sirtori F; Altomare A; Carini M; Aldini G; Regazzoni L
    Methods; 2018 Jul; 144():152-174. PubMed ID: 29890284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of frontal affinity chromatography with mass spectrometry (FAC-MS) for stereospecific ligand-macromolecule interaction, detection and screening.
    Slon-Usakiewicz JJ; Redden P
    Methods Mol Biol; 2009; 572():219-30. PubMed ID: 20694695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-macromolecule interactions in live cells by fluorescence correlation spectroscopy.
    Pramanik A
    Methods Mol Biol; 2009; 572():279-90. PubMed ID: 20694699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of native mass spectrometry in characterizing the structure and dynamics of macromolecular complexes.
    Boeri Erba E; Petosa C
    Protein Sci; 2015 Aug; 24(8):1176-92. PubMed ID: 25676284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native Mass Spectrometry in Fragment-Based Drug Discovery.
    Pedro L; Quinn RJ
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal affinity chromatography with MS detection of the ligand binding domain of PPARγ receptor: ligand affinity screening and stereoselective ligand-macromolecule interaction.
    Calleri E; Fracchiolla G; Montanari R; Pochetti G; Lavecchia A; Loiodice F; Laghezza A; Piemontese L; Massolini G; Temporini C
    J Chromatogr A; 2012 Apr; 1232():84-92. PubMed ID: 22056242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the differential stoichiometry and energetics of ligand binding to macromolecules by single-molecule force spectroscopy: an extended theory.
    Jacobson DR; Saleh OA
    J Phys Chem B; 2015 Feb; 119(5):1930-8. PubMed ID: 25621932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of protein-ligand interactions by mass spectrometry.
    Sinz A
    ChemMedChem; 2007 Apr; 2(4):425-31. PubMed ID: 17299828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity characterization-mass spectrometry methodology for quantitative analyses of small molecule protein binding in solution.
    Vilenchik LZ; Sheth PR; Chuang CC; Le HV
    Anal Biochem; 2011 Nov; 418(1):10-8. PubMed ID: 21726521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ion mobility-mass spectrometry of intact protein--ligand complexes for pharmaceutical drug discovery and development.
    Niu S; Rabuck JN; Ruotolo BT
    Curr Opin Chem Biol; 2013 Oct; 17(5):809-17. PubMed ID: 23856053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes.
    Hofstadler SA; Sannes-Lowery KA
    Nat Rev Drug Discov; 2006 Jul; 5(7):585-95. PubMed ID: 16816839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Exactive Plus EMR for automated protein-ligand screening by non-covalent mass spectrometry.
    Maple HJ; Scheibner O; Baumert M; Allen M; Taylor RJ; Garlish RA; Bromirski M; Burnley RJ
    Rapid Commun Mass Spectrom; 2014 Jul; 28(13):1561-8. PubMed ID: 24861608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Intact Macromolecular Complexes Using Native Mass Spectrometry.
    Boeri Erba E; Signor L; Oliva MF; Hans F; Petosa C
    Methods Mol Biol; 2018; 1764():133-151. PubMed ID: 29605913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The aromatic stacking interactions between proteins and their macromolecular ligands.
    Rahman MM; Muhseen ZT; Junaid M; Zhang H
    Curr Protein Pept Sci; 2015; 16(6):502-12. PubMed ID: 26138814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities.
    Agrahari V; Agrahari V; Mitra AK
    Ther Deliv; 2016; 7(4):257-78. PubMed ID: 27010987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-ALIS: Methodology for screening soluble RNAs as small molecule targets using ALIS affinity-selection mass spectrometry.
    Rizvi NF; Nickbarg EB
    Methods; 2019 Sep; 167():28-38. PubMed ID: 31059829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrogen-deuterium exchange mass spectrometry for determining protein structural changes in drug discovery.
    Lee JJ; Park YS; Lee KJ
    Arch Pharm Res; 2015 Oct; 38(10):1737-45. PubMed ID: 25743629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.